Alveolar type II epithelial cell (ATII)

Alveolar type II (ATII) epithelial cells, also known as type II pneumocytes, are specialized cuboidal cells that play a fundamental role in pulmonary physiology and lung defense. Their primary function is the production and secretion of pulmonary surfactant, a complex of phospholipids and proteins that reduces surface tension at the air-liquid interface to prevent alveolar collapse during expiration (StatPearls, 2023). Beyond their secretory role, ATII cells serve as the resident progenitor cells for the alveolar epithelium; they possess the unique ability to self-renew and differentiate into alveolar type I (ATI) cells to restore the gas-exchange surface following injury (Nature Reviews Molecular Cell Biology, 2019). In clinical pathology, ATII cells are the primary targets for SARS-CoV-2 infection, as they express high levels of the ACE2 receptor and TMPRSS2 protease, leading to the severe alveolar damage and inflammation seen in COVID-19 (The Lancet Respiratory Medicine, 2020). Furthermore, chronic ATII cell dysfunction, senescence, and impaired regenerative capacity are central drivers of Idiopathic Pulmonary Fibrosis (IPF), where these cells fail to effectively repair the epithelial lining (American Journal of Respiratory and Critical Care Medicine, 2020). Consequently, ATII cells are a major focus for therapeutic strategies ranging from surfactant replacement therapy to regenerative medicine and the development of anti-fibrotic drugs.

Other names

Type II pneumocyteAT2 cellGranular pneumocyteAlveolar epithelial type II cell

Drugs targeting these cells function by replacing deficient surfactant to restore alveolar surface tension, stimulating progenitor cell proliferation via growth factor receptors like KGFR, or inhibiting pro-fibrotic signaling cascades (e.g., TGF-beta or RTK pathways) within the cell to prevent epithelial-to-mesenchymal transition (StatPearls, 2023; Nature Reviews Molecular Cell Biology, 2019).